{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:40Z","timestamp":1792801120663,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ando.2024.05.022","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T02:18:40Z","timestamp":1718245120000},"page":"201-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Leptin replacement therapy in the management of lipodystrophy syndromes"],"prefix":"10.1016","volume":"85","author":[{"given":"Corinne","family":"Vigouroux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e9na","family":"Mosbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Vatier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2024.05.022_bib0240","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","article-title":"Weight-reducing effects of the plasma protein encoded by the obese gene","volume":"269","author":"Halaas","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.ando.2024.05.022_bib0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ando.2016.01.001","article-title":"New adipokines","volume":"77","author":"F\u00e8ve","year":"2016","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2024.05.022_bib0250","doi-asserted-by":"crossref","first-page":"bqaa204","DOI":"10.1210\/endocr\/bqaa204","article-title":"The importance of leptin to reproduction","volume":"162","author":"Childs","year":"2021","journal-title":"Endocrinology"},{"key":"10.1016\/j.ando.2024.05.022_bib0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cmet.2013.05.010","article-title":"Leptin at the intersection of neuroendocrinology and metabolism: current evidence and therapeutic perspectives","volume":"18","author":"Dalamaga","year":"2013","journal-title":"Cell Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0260","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrrheum.2016.209","article-title":"Leptin in the interplay of inflammation, metabolism and immune system disorders","volume":"13","author":"Abella","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ando.2024.05.022_bib0265","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/415339a","article-title":"Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase","volume":"415","author":"Minokoshi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ando.2024.05.022_bib0270","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJM199909163411204","article-title":"Effects of recombinant leptin therapy in a child with congenital leptin deficiency","volume":"341","author":"Farooqi","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2024.05.022_bib0275","first-page":"4000","article-title":"Editorial: leptin as a therapeutic agent--trials and tribulations","volume":"85","author":"Mantzoros","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0280","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2337\/db23-0571","article-title":"Leptin reduction as a required component for weight loss","volume":"73","author":"Zhao","year":"2024","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.05.022_bib0285","doi-asserted-by":"crossref","first-page":"104807","DOI":"10.1016\/j.neubiorev.2022.104807","article-title":"The role of hypoleptinemia in the psychological and behavioral adaptation to starvation: Implications for anorexia nervosa","volume":"141","author":"Hebebrand","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.ando.2024.05.022_bib0290","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ando.2019.10.003","article-title":"Lipodystrophic syndromes: from diagnosis to treatment","volume":"81","author":"Sollier","year":"2020","journal-title":"Ann Endocrinol"},{"key":"10.1016\/j.ando.2024.05.022_bib0295","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0300","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1101\/gad.12.20.3168","article-title":"Life without white fat: a transgenic mouse","volume":"12","author":"Moitra","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.ando.2024.05.022_bib0305","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1101\/gad.12.20.3182","article-title":"Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy","volume":"12","author":"Shimomura","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.ando.2024.05.022_bib0310","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1172\/JCI7901","article-title":"Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice","volume":"105","author":"Gavrilova","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2024.05.022_bib0315","doi-asserted-by":"crossref","first-page":"8456","DOI":"10.1074\/jbc.275.12.8456","article-title":"Mechanism of insulin resistance in A-ZIP\/F-1 fatless mice","volume":"275","author":"Kim","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ando.2024.05.022_bib0320","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.2337\/diabetes.51.9.2727","article-title":"Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy","volume":"51","author":"Colombo","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.05.022_bib0325","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.biochi.2004.11.014","article-title":"Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine","volume":"87","author":"Unger","year":"2005","journal-title":"Biochimie"},{"key":"10.1016\/j.ando.2024.05.022_bib0330","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ando.2024.05.022_bib0335","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.2337\/diabetes.50.6.1440","article-title":"Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes","volume":"50","author":"Ebihara","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.05.022_bib0340","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ando.2024.05.022_bib0345","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2024.05.022_bib0350","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1210\/jc.2012-1872","article-title":"Functional magnetic resonance imaging analysis of food-related brain activity in patients with lipodystrophy undergoing leptin replacement therapy","volume":"97","author":"Aotani","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0355","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jhep.2013.02.007","article-title":"The liver diseases of lipodystrophy: the long-term effect of leptin treatment","volume":"59","author":"Safar Zadeh","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.ando.2024.05.022_bib0360","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2337\/db15-1550","article-title":"Leptin substitution in patients with lipodystrophy: neural correlates for long-term success in the normalization of eating behavior","volume":"65","author":"Schl\u00f6gl","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.05.022_bib0365","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/dom.12606","article-title":"One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes","volume":"18","author":"Vatier","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0370","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.diabet.2016.08.004","article-title":"One-year metreleptin therapy decreases PCSK9 serum levels in diabetic patients with monogenic lipodystrophy syndromes","volume":"43","author":"Vatier","year":"2017","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0375","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13023-019-1141-2","article-title":"Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes","volume":"14","author":"Vatier","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ando.2024.05.022_bib0380","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11892-018-1100-7","article-title":"Update on therapeutic options in lipodystrophy","volume":"18","author":"Akinci","year":"2018","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.ando.2024.05.022_bib0385","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.metabol.2004.08.021","article-title":"The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients","volume":"54","author":"Musso","year":"2005","journal-title":"Metabolism"},{"key":"10.1016\/j.ando.2024.05.022_bib0390","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1542\/peds.2006-3165","article-title":"Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy","volume":"120","author":"Beltrand","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.ando.2024.05.022_bib0395","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1172\/JCI95476","article-title":"Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy","volume":"128","author":"Brown","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2024.05.022_bib0400","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","article-title":"Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy","volume":"56","author":"Park","year":"2007","journal-title":"Metabolism"},{"key":"10.1016\/j.ando.2024.05.022_bib0405","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","article-title":"Efficacy of leptin therapy in the different forms of human lipodystrophy","volume":"53","author":"Chong","year":"2010","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2024.05.022_bib0410","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1210\/jc.2014-4491","article-title":"Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin","volume":"100","author":"Diker-Cohen","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0415","first-page":"659","article-title":"Efficacy and safety of metreleptin in patients with partial lipodystrophy: lessons from an expanded access program","volume":"7","author":"Ajluni","year":"2016","journal-title":"J Diabetes Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0420","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s12020-019-01862-8","article-title":"Long-term effectiveness and safety of metreleptin in the treatment of patients with partial lipodystrophy","volume":"64","author":"Oral","year":"2019","journal-title":"Endocrine"},{"key":"10.1016\/j.ando.2024.05.022_bib0425","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1080\/03007995.2021.1976125","article-title":"Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use","volume":"37","author":"Adamski","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ando.2024.05.022_bib0430","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/dom.14726","article-title":"Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: real-life experience from a national reference network","volume":"24","author":"Mosbah","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0435","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cen.12980","article-title":"Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy","volume":"85","author":"Chan","year":"2016","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.ando.2024.05.022_bib0440","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1530\/EJE-09-1027","article-title":"Resistance to leptin-replacement therapy in Berardinelli-Seip congenital lipodystrophy: an immunological origin","volume":"162","author":"Beltrand","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.05.022_bib0445","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/10428194.2015.1040015","article-title":"Lymphoma in acquired generalized lipodystrophy","volume":"57","author":"Brown","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ando.2024.05.022_bib0450","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1210\/jc.2016-2466","article-title":"The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline","volume":"101","author":"Brown","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.05.022_bib0455","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13023-022-02308-7","article-title":"Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole national de diagnostic et de soins)","volume":"17","author":"Mosbah","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ando.2024.05.022_bib0460","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13023-023-02714-5","article-title":"The metreleptin effectiveness and safety registry (MEASuRE): concept, design and challenges","volume":"18","author":"Haymond","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ando.2024.05.022_bib0465","unstructured":"Ceccarini G, Akinci B, Araujo-Vilar D, Beghini M, Brown RJ, Carrion Tudela J, Corradin V, Donadille B, Jerez Ruiz J, Jeru I, Lattanzi G, Maffei M, Mcilroy GD, Nob\u00e9court E, Perez de Tudela N, Rochford JJ, Sanders R, von Schnurbein J, Tews D, Vantyghem MC, Vatier C, Vigouroux C, Santini F. Proceedings of the annual meeting of the European Consortium of Lipodystrophies (ECLip) Pisa, Italy, 28\u201329 September 2023. Ann Endocrinol in press."},{"key":"10.1016\/j.ando.2024.05.022_bib0470","doi-asserted-by":"crossref","first-page":"eadd4897","DOI":"10.1126\/scitranslmed.add4897","article-title":"Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency","volume":"15","author":"Altarejos","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ando.2024.05.022_bib471","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13762","article-title":"Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first-in-human phase I study","volume":"17","author":"Gewitz","year":"2024","journal-title":"Clin Transl Sci"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426624000775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426624000775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T22:31:05Z","timestamp":1723329065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426624000775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S0003426624000775"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2024.05.022","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leptin replacement therapy in the management of lipodystrophy syndromes","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2024.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}